483 related articles for article (PubMed ID: 30275151)
1. Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.
Slivicki RA; Saberi SA; Iyer V; Vemuri VK; Makriyannis A; Hohmann AG
J Pharmacol Exp Ther; 2018 Dec; 367(3):551-563. PubMed ID: 30275151
[TBL] [Abstract][Full Text] [Related]
2. Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro.
Slivicki RA; Xu Z; Mali SS; Hohmann AG
Pharmacol Res; 2019 Apr; 142():267-282. PubMed ID: 30739035
[TBL] [Abstract][Full Text] [Related]
3. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment.
Guindon J; Lai Y; Takacs SM; Bradshaw HB; Hohmann AG
Pharmacol Res; 2013 Jan; 67(1):94-109. PubMed ID: 23127915
[TBL] [Abstract][Full Text] [Related]
4. The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors.
da Fonseca Pacheco D; Klein A; de Castro Perez A; da Fonseca Pacheco CM; de Francischi JN; Duarte ID
Br J Pharmacol; 2008 Jul; 154(5):1143-9. PubMed ID: 18469844
[TBL] [Abstract][Full Text] [Related]
5. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain.
Kinsey SG; Long JZ; O'Neal ST; Abdullah RA; Poklis JL; Boger DL; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2009 Sep; 330(3):902-10. PubMed ID: 19502530
[TBL] [Abstract][Full Text] [Related]
6. Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy.
Nasirinezhad F; Jergova S; Pearson JP; Sagen J
Neuropharmacology; 2015 Aug; 95():100-9. PubMed ID: 25486617
[TBL] [Abstract][Full Text] [Related]
7. The cannabinoid CB
Iyer V; Slivicki RA; Thomaz AC; Crystal JD; Mackie K; Hohmann AG
Eur J Pharmacol; 2020 Nov; 886():173544. PubMed ID: 32896549
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Fatty Acid Amide Hydrolase Improves Depressive-Like Behaviors Independent of Its Peripheral Antinociceptive Effects in a Rat Model of Neuropathic Pain.
Jiang HX; Ke BW; Liu J; Ma G; Hai KR; Gong DY; Yang Z; Zhou C
Anesth Analg; 2019 Aug; 129(2):587-597. PubMed ID: 29863609
[TBL] [Abstract][Full Text] [Related]
9. Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence.
Slivicki RA; Xu Z; Kulkarni PM; Pertwee RG; Mackie K; Thakur GA; Hohmann AG
Biol Psychiatry; 2018 Nov; 84(10):722-733. PubMed ID: 28823711
[TBL] [Abstract][Full Text] [Related]
10. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors.
Desroches J; Charron S; Bouchard JF; Beaulieu P
Neuropharmacology; 2014 Feb; 77():441-52. PubMed ID: 24148808
[TBL] [Abstract][Full Text] [Related]
11. Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception.
Naidu PS; Booker L; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2009 Apr; 329(1):48-56. PubMed ID: 19118134
[TBL] [Abstract][Full Text] [Related]
12. Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase.
Haller VL; Stevens DL; Welch SP
Eur J Pharmacol; 2008 Dec; 600(1-3):50-8. PubMed ID: 18762181
[TBL] [Abstract][Full Text] [Related]
13. Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions.
Sasso O; Bertorelli R; Bandiera T; Scarpelli R; Colombano G; Armirotti A; Moreno-Sanz G; Reggiani A; Piomelli D
Pharmacol Res; 2012 May; 65(5):553-63. PubMed ID: 22420940
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms.
Spradley JM; Guindon J; Hohmann AG
Pharmacol Res; 2010 Sep; 62(3):249-58. PubMed ID: 20416378
[TBL] [Abstract][Full Text] [Related]
15. The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice.
Booker L; Kinsey SG; Abdullah RA; Blankman JL; Long JZ; Ezzili C; Boger DL; Cravatt BF; Lichtman AH
Br J Pharmacol; 2012 Apr; 165(8):2485-96. PubMed ID: 21506952
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice.
Nozaki C; Markert A; Zimmer A
Eur Neuropsychopharmacol; 2015 Aug; 25(8):1388-96. PubMed ID: 25910421
[TBL] [Abstract][Full Text] [Related]
17. Peripheral deficiency and antiallodynic effects of 2-arachidonoyl glycerol in a mouse model of paclitaxel-induced neuropathic pain.
Thomas A; Okine BN; Finn DP; Masocha W
Biomed Pharmacother; 2020 Sep; 129():110456. PubMed ID: 32603895
[TBL] [Abstract][Full Text] [Related]
18. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
Haller VL; Cichewicz DL; Welch SP
Eur J Pharmacol; 2006 Sep; 546(1-3):60-8. PubMed ID: 16919265
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal.
Li AL; Lin X; Dhopeshwarkar AS; Thomaz AC; Carey LM; Liu Y; Nikas SP; Makriyannis A; Mackie K; Hohmann AG
Mol Pharmacol; 2019 Feb; 95(2):155-168. PubMed ID: 30504240
[TBL] [Abstract][Full Text] [Related]
20. Effects of alterations in cannabinoid signaling, alone and in combination with morphine, on pain-elicited and pain-suppressed behavior in mice.
Miller LL; Picker MJ; Umberger MD; Schmidt KT; Dykstra LA
J Pharmacol Exp Ther; 2012 Jul; 342(1):177-87. PubMed ID: 22514333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
